Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastatis and death

Cancer

Volumn 109, Issue 1, 2007, Pages 41-47

  Alcántara, Pino ^a   Hanlon, Alexandra ^b   Buyyounouski, Mark K ^a   Horwitz, Eric M ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

3D conformal radiotherapy; Cause specific mortality; Distant metastasis; Prostate cancer; Prostate specific antigen nadir

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33846328771     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22341     Document Type: Article

References (31)

1. Zietman AL, Tibbs MK, Dallow KC, et al. Use of PSA nadir to predict subsequent biochemical outcome after external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1996;40:159-162.
2. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol. 1996;156:450-453.
3. Critz FA, Levinson AK, Williams WH, Holladay DA, Holladay CT. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 1997;49:322-326.
4. Critz FA, Williams WH, Holladay CT, et al. Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 1999;54:968-971.
5. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys. 1994;30:279-287.
6. Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer. 1999;86:1557-1566.
7. Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys. 2002;53:304-315.
8. Perez CA, Michalski JM, Lockett MA. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys. 2001;49:1287-1296.
9. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, Esche BA. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer. 1997;79:328-336.
10. Zelefsky M, Leibel S, Gaudin P, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491-500.
11. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48:355-367.
12. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002;54:677-685.
13. Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006;64:1140-1150.
14. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:297-303.
15. Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:19-23.
16. Cavanaugh SX, Kupelian PA, Fuller CD, et al. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model. Cancer. 2004;101:96-105.
17. Johnstone PA, Williams SR, Riffenburgh RH. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7:263-267.
18. Cavanaugh SX, Fuller CD, Kupelian PA, et al. Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer Prostatic Dis. 2005;8:353-358.
19. Feigenberg S, Horwitz E, Uzzo R, et al. Post-treatment PSA values within 6 months of 3D conformal radiotherapy for prostate cancer predict for distant metastases. Int J Radiat Oncol Biol Phys. 2004;60:S234-S235.
20. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 1993;72:832-842.
21. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995;32:293-306.
22. Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281-1287.
23. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys. 2005;61:695-701.
24. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004;100:538-543.
25. Monti AF, Ostinelli A, Frigerio M, et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol. 1995;35:145-150.
26. Cox J, Grignon D, Kaplan R, Parsons J, Schellhammer P. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
27. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:447-457.
29. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
30. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172:S42-46; discussion S46-47.
31. Nickers P, Albert A, Waltregny D, Deneufbourg JM. Prognostic value of PSA nadir ≤4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2006;65:73-77.